Covid-19 roundup: Experts worry molnupiravir demand will leave poor countries behind as Merck says it will double production
As Merck’s highly anticipated Covid-19 antiviral pill awaits emergency use authorization from the FDA, countries are lining up for supply contracts, which likely could leave poorer nations behind, in a rollout that may be similar to the vaccines.
About 10 countries have signed on to use the antiviral, including several Asian-Pacifica countries such as Thailand, India, Australia, South Korea, and Malaysia. In the US, Merck agreed to supply 1.7 million doses earlier this year for about about $1.2 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
